Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

[Incidence and Predictive Factors for Bilaterality in Patients with Papillary Thyroid Carcinoma].

Jo P, Kesruek H, Nietert M, Sahlmann CO, Gaedcke J, Ghadimi M, Sperling J.

Zentralbl Chir. 2018 Aug;143(4):361-366. doi: 10.1055/a-0651-0878. Epub 2018 Aug 22. German.

PMID:
30134494
2.

Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94.

Sprenger T, Beißbarth T, Sauer R, Tschmelitsch J, Fietkau R, Liersch T, Hohenberger W, Staib L, Gaedcke J, Raab HR, Rödel C, Ghadimi M.

Br J Surg. 2018 Oct;105(11):1510-1518. doi: 10.1002/bjs.10877. Epub 2018 May 30.

PMID:
29846017
3.

A comparative study of RNA-Seq and microarray data analysis on the two examples of rectal-cancer patients and Burkitt Lymphoma cells.

Wolff A, Bayerlová M, Gaedcke J, Kube D, Beißbarth T.

PLoS One. 2018 May 16;13(5):e0197162. doi: 10.1371/journal.pone.0197162. eCollection 2018.

4.

Colorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery.

Hu Y, Gaedcke J, Emons G, Beissbarth T, Grade M, Jo P, Yeager M, Chanock SJ, Wolff H, Camps J, Ghadimi BM, Ried T.

Genes Chromosomes Cancer. 2018 Mar;57(3):140-149. doi: 10.1002/gcc.22512. Epub 2017 Nov 28.

PMID:
29119627
5.

Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling.

Emons G, Spitzner M, Reineke S, Möller J, Auslander N, Kramer F, Hu Y, Beissbarth T, Wolff HA, Rave-Fränk M, Heßmann E, Gaedcke J, Ghadimi BM, Johnsen SA, Ried T, Grade M.

Mol Cancer Res. 2017 Nov;15(11):1481-1490. doi: 10.1158/1541-7786.MCR-17-0205. Epub 2017 Aug 15.

6.

ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.

Perkhofer L, Schmitt A, Romero Carrasco MC, Ihle M, Hampp S, Ruess DA, Hessmann E, Russell R, Lechel A, Azoitei N, Lin Q, Liebau S, Hohwieler M, Bohnenberger H, Lesina M, Algül H, Gieldon L, Schröck E, Gaedcke J, Wagner M, Wiesmüller L, Sipos B, Seufferlein T, Reinhardt HC, Frappart PO, Kleger A.

Cancer Res. 2017 Oct 15;77(20):5576-5590. doi: 10.1158/0008-5472.CAN-17-0634. Epub 2017 Aug 8.

7.

Changes of Microrna Levels in Plasma of Patients with Rectal Cancer during Chemoradiotherapy.

Jo P, Azizian A, Salendo J, Kramer F, Bernhardt M, Wolff HA, Gruber J, Grade M, Beißbarth T, Ghadimi BM, Gaedcke J.

Int J Mol Sci. 2017 May 27;18(6). pii: E1140. doi: 10.3390/ijms18061140.

8.

Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.

Chen NM, Neesse A, Dyck ML, Steuber B, Koenig AO, Lubeseder-Martellato C, Winter T, Forster T, Bohnenberger H, Kitz J, Reuter-Jessen K, Griesmann H, Gaedcke J, Grade M, Zhang JS, Tsai WC, Siveke J, Schildhaus HU, Ströbel P, Johnsen SA, Ellenrieder V, Hessmann E.

Gastroenterology. 2017 May;152(6):1507-1520.e15. doi: 10.1053/j.gastro.2017.01.043. Epub 2017 Feb 8.

9.

Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer.

Wang J, Yang S, He P, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Gaida MM, Hanna N, Alexander HR, Hussain SP.

Clin Cancer Res. 2016 Dec 15;22(24):5992-6001. Epub 2016 Jul 8.

10.

Neoadjuvant Therapy in Rectal Cancer - Biobanking of Preoperative Tumor Biopsies.

Jo P, Nietert M, Gusky L, Kitz J, Conradi LC, Müller-Dornieden A, Schüler P, Wolff HA, Rüschoff J, Ströbel P, Grade M, Liersch T, Beißbarth T, Ghadimi MB, Sax U, Gaedcke J.

Sci Rep. 2016 Oct 18;6:35589. doi: 10.1038/srep35589.

11.

Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer.

Wang J, He P, Gaida M, Yang S, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis H, Lee D, Weiss JM, Stauffer J, Hanna N, Alexander HR, Hussain SP.

Oncotarget. 2016 Aug 16;7(33):52993-53004. doi: 10.18632/oncotarget.10323.

12.

A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.

Yang S, He P, Wang J, Schetter A, Tang W, Funamizu N, Yanaga K, Uwagawa T, Satoskar AR, Gaedcke J, Bernhardt M, Ghadimi BM, Gaida MM, Bergmann F, Werner J, Ried T, Hanna N, Alexander HR, Hussain SP.

Cancer Res. 2016 Jul 1;76(13):3838-50. doi: 10.1158/0008-5472.CAN-15-2841. Epub 2016 Apr 20.

13.

MicroRNA in rectal cancer.

Azizian A, Gruber J, Ghadimi BM, Gaedcke J.

World J Gastrointest Oncol. 2016 May 15;8(5):416-26. doi: 10.4251/wjgo.v8.i5.416. Review.

14.

[Recurrent seizures of unknown aetiology].

Krauß M, Berkermann H, Ghadimi M, Gaedcke J, Bürger T.

Dtsch Med Wochenschr. 2016 Apr;141(9):631-3. doi: 10.1055/s-0041-103982. Epub 2016 Apr 28. German.

PMID:
27123728
15.

Prognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer.

Azizian A, Epping I, Kramer F, Jo P, Bernhardt M, Kitz J, Salinas G, Wolff HA, Grade M, Beißbarth T, Ghadimi BM, Gaedcke J.

Int J Mol Sci. 2016 Apr 15;17(4):568. doi: 10.3390/ijms17040568.

16.

Heterogeneity of KRAS Mutation Status in Rectal Cancer.

Jo P, König A, Schirmer M, Kitz J, Conradi LC, Azizian A, Bernhardt M, Wolff HA, Grade M, Ghadimi M, Ströbel P, Schildhaus HU, Gaedcke J.

PLoS One. 2016 Apr 11;11(4):e0153278. doi: 10.1371/journal.pone.0153278. eCollection 2016.

17.

Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.

Schirmer MA, Lüske CM, Roppel S, Schaudinn A, Zimmer C, Pflüger R, Haubrock M, Rapp J, Güngör C, Bockhorn M, Hackert T, Hank T, Strobel O, Werner J, Izbicki JR, Johnsen SA, Gaedcke J, Brockmöller J, Ghadimi BM.

J Natl Cancer Inst. 2016 Feb 8;108(5). doi: 10.1093/jnci/djv387. Print 2016 May.

18.

EEPD1 Rescues Stressed Replication Forks and Maintains Genome Stability by Promoting End Resection and Homologous Recombination Repair.

Wu Y, Lee SH, Williamson EA, Reinert BL, Cho JH, Xia F, Jaiswal AS, Srinivasan G, Patel B, Brantley A, Zhou D, Shao L, Pathak R, Hauer-Jensen M, Singh S, Kong K, Wu X, Kim HS, Beissbarth T, Gaedcke J, Burma S, Nickoloff JA, Hromas RA.

PLoS Genet. 2015 Dec 18;11(12):e1005675. doi: 10.1371/journal.pgen.1005675. eCollection 2015 Dec.

19.

Reduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated arc therapy and 3D conformal radiotherapy.

Dröge LH, Weber HE, Guhlich M, Leu M, Conradi LC, Gaedcke J, Hennies S, Herrmann MK, Rave-Fränk M, Wolff HA.

BMC Cancer. 2015 Oct 20;15:750. doi: 10.1186/s12885-015-1812-x.

20.

The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability.

Lüddecke S, Ertych N, Stenzinger A, Weichert W, Beissbarth T, Dyczkowski J, Gaedcke J, Valerius O, Braus GH, Kschischo M, Bastians H.

Oncogene. 2016 May 5;35(18):2398-406. doi: 10.1038/onc.2015.290. Epub 2015 Aug 24.

PMID:
26300001
21.

The oxidative demethylase ALKBH3 marks hyperactive gene promoters in human cancer cells.

Liefke R, Windhof-Jaidhauser IM, Gaedcke J, Salinas-Riester G, Wu F, Ghadimi M, Dango S.

Genome Med. 2015 Jun 30;7(1):66. doi: 10.1186/s13073-015-0180-0. eCollection 2015.

22.

Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition.

Russell R, Perkhofer L, Liebau S, Lin Q, Lechel A, Feld FM, Hessmann E, Gaedcke J, Güthle M, Zenke M, Hartmann D, von Figura G, Weissinger SE, Rudolph KL, Möller P, Lennerz JK, Seufferlein T, Wagner M, Kleger A.

Nat Commun. 2015 Jul 29;6:7677. doi: 10.1038/ncomms8677.

23.

MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.

Zhang X, Schulz R, Edmunds S, Krüger E, Markert E, Gaedcke J, Cormet-Boyaka E, Ghadimi M, Beissbarth T, Levine AJ, Moll UM, Dobbelstein M.

Mol Cell. 2015 Jul 16;59(2):243-57. doi: 10.1016/j.molcel.2015.05.036. Epub 2015 Jul 2.

24.

Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma: Effects on treatment-related side effects and survival.

Weber HE, Dröge LH, Hennies S, Herrmann MK, Gaedcke J, Wolff HA.

Strahlenther Onkol. 2015 Nov;191(11):827-34. doi: 10.1007/s00066-015-0859-6. Epub 2015 Jun 8.

PMID:
26050046
25.

Preoperative Prediction of Lymph Node Status by Circulating Mir-18b and Mir-20a During Chemoradiotherapy in Patients with Rectal Cancer.

Azizian A, Kramer F, Jo P, Wolff HA, Beißbarth T, Skarupke R, Bernhardt M, Grade M, Ghadimi BM, Gaedcke J.

World J Surg. 2015 Sep;39(9):2329-35. doi: 10.1007/s00268-015-3083-8.

PMID:
25990502
26.

5-Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair.

Srinivas US, Dyczkowski J, Beißbarth T, Gaedcke J, Mansour WY, Borgmann K, Dobbelstein M.

Oncotarget. 2015 May 20;6(14):12574-86.

27.

Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity.

Singh SK, Chen NM, Hessmann E, Siveke J, Lahmann M, Singh G, Voelker N, Vogt S, Esposito I, Schmidt A, Brendel C, Stiewe T, Gaedcke J, Mernberger M, Crawford HC, Bamlet WR, Zhang JS, Li XK, Smyrk TC, Billadeau DD, Hebrok M, Neesse A, Koenig A, Ellenrieder V.

EMBO J. 2015 Feb 12;34(4):517-30. doi: 10.15252/embj.201489574. Epub 2015 Jan 13.

28.

Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer.

Gaedcke J, Leha A, Claus R, Weichenhan D, Jung K, Kitz J, Grade M, Wolff HA, Jo P, Doyen J, Gérard JP, Johnsen SA, Plass C, Beißbarth T, Ghadimi M.

Oncotarget. 2014 Sep 30;5(18):8123-35.

29.

Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells.

Hara T, Jones MF, Subramanian M, Li XL, Ou O, Zhu Y, Yang Y, Wakefield LM, Hussain SP, Gaedcke J, Ried T, Luo J, Caplen NJ, Lal A.

Oncotarget. 2014 Sep 15;5(17):7635-50.

30.

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.

Landmann H, Proia DA, He S, Ogawa LS, Kramer F, Beißbarth T, Grade M, Gaedcke J, Ghadimi M, Moll U, Dobbelstein M.

Cell Death Dis. 2014 Sep 11;5:e1411. doi: 10.1038/cddis.2014.378.

31.

CFTR, SPINK1, PRSS1, and CTRC mutations are not associated with pancreatic cancer in German patients.

Schubert S, Traub F, Brakensiek K, von Kopylow K, Marohn B, Maelzer M, Gaedcke J, Kreipe H, Stuhrmann M.

Pancreas. 2014 Oct;43(7):1078-82. doi: 10.1097/MPA.0000000000000166.

PMID:
25003218
32.

High-resolution analysis of DNA copy number alterations in rectal cancer: correlation with metastasis, survival, and mRNA expression.

Doyen J, Letouzé E, Marisa L, de Reyniès A, Milano G, Etienne-Grimaldi MC, Olschwang S, Gaedcke J, Ghadimi M, Gérard JP.

Strahlenther Onkol. 2014 Oct;190(11):1028-36. doi: 10.1007/s00066-014-0659-4. Epub 2014 Apr 26.

PMID:
24770938
33.

Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury.

Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, Gaedcke J, Moerer O, Slotta JE, Walson P, Kollmar O, Oellerich M, Schütz E.

Clin Chem. 2013 Dec;59(12):1732-41. doi: 10.1373/clinchem.2013.210328. Epub 2013 Sep 23.

34.

STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo.

Spitzner M, Roesler B, Bielfeld C, Emons G, Gaedcke J, Wolff HA, Rave-Fränk M, Kramer F, Beissbarth T, Kitz J, Wienands J, Ghadimi BM, Ebner R, Ried T, Grade M.

Int J Cancer. 2014 Feb 15;134(4):997-1007. doi: 10.1002/ijc.28429. Epub 2013 Sep 3.

35.

Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.

Salendo J, Spitzner M, Kramer F, Zhang X, Jo P, Wolff HA, Kitz J, Kaulfuß S, Beißbarth T, Dobbelstein M, Ghadimi M, Grade M, Gaedcke J.

Radiother Oncol. 2013 Sep;108(3):451-7. doi: 10.1016/j.radonc.2013.06.032. Epub 2013 Aug 7.

PMID:
23932154
36.

Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer.

Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, Hanna N, Alexander HR, Hussain SP.

Clin Cancer Res. 2013 Sep 15;19(18):4983-93. doi: 10.1158/1078-0432.CCR-13-0209. Epub 2013 Aug 5.

37.

FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer.

Zhang G, He P, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Hanna N, Alexander HR, Hussain SP.

Cancer Res. 2013 Sep 1;73(17):5416-25. doi: 10.1158/0008-5472.CAN-13-0362. Epub 2013 Jun 25.

38.

Increasing toxicity during neoadjuvant radiochemotherapy as positive prognostic factor for patients with esophageal carcinoma.

Hennies S, Hermann RM, Gaedcke J, Grade M, Hess CF, Christiansen H, Wolff HA.

Dis Esophagus. 2014 Feb-Mar;27(2):146-51. doi: 10.1111/dote.12067. Epub 2013 Apr 9.

PMID:
23574528
39.

Emergency repair of giant inguinoscrotal hernia in a septic patient.

Gaedcke J, Schüler P, Brinker J, Quintel M, Ghadimi M.

J Gastrointest Surg. 2013 Apr;17(4):837-9. doi: 10.1007/s11605-012-2136-7. Epub 2013 Jan 9.

40.

Frequency of HER-2 positivity in rectal cancer and prognosis.

Conradi LC, Styczen H, Sprenger T, Wolff HA, Rödel C, Nietert M, Homayounfar K, Gaedcke J, Kitz J, Talaulicar R, Becker H, Ghadimi M, Middel P, Beissbarth T, Rüschoff J, Liersch T.

Am J Surg Pathol. 2013 Apr;37(4):522-31. doi: 10.1097/PAS.0b013e318272ff4d.

PMID:
23282976
41.

Molecular patterns in the evolution of serrated lesion of the colorectum.

Gaiser T, Meinhardt S, Hirsch D, Killian JK, Gaedcke J, Jo P, Ponsa I, Miró R, Rüschoff J, Seitz G, Hu Y, Camps J, Ried T.

Int J Cancer. 2013 Apr 15;132(8):1800-10. doi: 10.1002/ijc.27869. Epub 2012 Oct 17.

42.

PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.

Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, Newsome G, Goldenberg DM.

Cancer. 2013 Feb 1;119(3):522-8. doi: 10.1002/cncr.27762. Epub 2012 Aug 16.

43.

Testicular radiation dose after multimodal curative therapy for locally advanced rectal cancer. Influence on hormone levels, quality of life, and sexual functioning.

Hennies S, Wolff HA, Jung K, Rave-Fränk M, Gaedcke J, Ghadimi M, Hess CF, Becker H, Hermann RM, Christiansen H.

Strahlenther Onkol. 2012 Oct;188(10):926-32. Epub 2012 Aug 11.

PMID:
22878546
44.

The rectal cancer microRNAome--microRNA expression in rectal cancer and matched normal mucosa.

Gaedcke J, Grade M, Camps J, Søkilde R, Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi BM, Møller S, Beissbarth T, Ried T, Litman T.

Clin Cancer Res. 2012 Sep 15;18(18):4919-30. Epub 2012 Jul 31.

45.

Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.

Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, Lee DH, Subleski J, Chan T, Weiss JM, Back TC, Yanaga K, Hanna N, Alexander HR, Maitra A, Hussain SP.

Int J Cancer. 2013 Feb 15;132(4):785-94. doi: 10.1002/ijc.27736.

46.

The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies.

Grade M, Wolff HA, Gaedcke J, Ghadimi BM.

Langenbecks Arch Surg. 2012 Apr;397(4):543-55. doi: 10.1007/s00423-012-0929-5. Epub 2012 Mar 2. Review.

47.

DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.

Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, Lacy C, Maitra A, Hanna N, Alexander HR, Hussain SP.

PLoS One. 2012;7(2):e31507. doi: 10.1371/journal.pone.0031507. Epub 2012 Feb 20.

48.

Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers.

Sharon E, Zhang J, Hollevoet K, Steinberg SM, Pastan I, Onda M, Gaedcke J, Ghadimi BM, Ried T, Hassan R.

Clin Chem Lab Med. 2012 Apr;50(4):721-5. doi: 10.1515/CCLM.2011.816.

PMID:
22149739
49.

CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer.

Jo P, Jung K, Grade M, Conradi LC, Wolff HA, Kitz J, Becker H, Rüschoff J, Hartmann A, Beissbarth T, Müller-Dornieden A, Ghadimi M, Schneider-Stock R, Gaedcke J.

Surgery. 2012 Apr;151(4):564-70. doi: 10.1016/j.surg.2011.08.013. Epub 2011 Oct 14.

PMID:
22001634
50.

Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant.

Schirmer MA, Mergler CP, Rave-Fränk M, Herrmann MK, Hennies S, Gaedcke J, Conradi LC, Jo P, Beissbarth T, Hess CF, Becker H, Ghadimi M, Brockmöller J, Christiansen H, Wolff HA.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):149-57. doi: 10.1016/j.ijrobp.2011.05.063. Epub 2011 Oct 12.

PMID:
22000747

Supplemental Content

Loading ...
Support Center